Salute e Benessere

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax"…

The film tells a series of touching COVID-19 vaccine scientific research stories from three perspectives, namely, China's vaccine research, production, and science, and features interviews with numerous key personnel from world-leading institutions, including Zhong Nanshan, an academician with the Chinese Academy of Engineering; Ben Cowling, an epidemiologist of School of Public Health, University of Hong Kong, as well as production experts and scholars around the world related to Covid-19…
PR Newswire
02/10/2023

LifeArc welcomes Stéphane Maikovsky as Interim CEO

LifeArc welcomes Stéphane Maikovsky as Interim CEO2 October 2023- LifeArc, the self-funded, not-for-profit medical research organisation today announced the appointment of Stéphane Maikovsky as Interim Chief Executive Officer (CEO), succeeding Dr Melanie Lee who stepped down from the role last month.Stéphane joined LifeArc as Chief Financial Officer (CFO) and Trustee in June 2022 to lead the organisation's Finance, Investment, Early Ventures, Information Technology and...
Nasdaq GlobeNewswire
02/10/2023

Groupe Casino: Groupement Les Mousquetaires and Casino Group have completed the…

Groupement Les Mousquetaires and Casino Group have completed the sale of a first set of 61 stores and extended their partnerships to include purchasing and supply Paris, 2 October 2023 Pursuant to the memorandum of understanding signed on 26 May 2023, Groupement Les Mousquetaires and Casino Group have agreed to the: sale of a group of 61 Casino France outlets (Hypermarkets, Supermarkets, Franprix and convenience stores) representing sales of €563 million excluding VAT (i.e., €621...
Nasdaq GlobeNewswire
02/10/2023

Basilea announces FDA acceptance of New Drug Application for antibiotic…

Seeking approval forStaphylococcus aureusbacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, October 02, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Nasdaq GlobeNewswire
02/10/2023

Novartis investigational iptacopan Phase III study demonstrates clinically…

Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction 1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system 2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney...
Nasdaq GlobeNewswire
02/10/2023

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023…

Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and...
Nasdaq GlobeNewswire
02/10/2023

Navigating Hemophilia Disease Market: Healthcare Consulting Services, Disease…

How is Haemophilia turning into a global concern? How is Haemophilia turning into a global concern? Haemophilia epidemiological data suggests that more than 400 babies are born with haemophilia each year. This concerning data has escalated the demand for efficient haemophilia healthcare solutions. Once diagnosed, the patient is required to stay under complete medical surveillance throughout their lives. The fact that this ailment has no permanent cure makes it highly dangerous. Even minor...
PR Newswire
02/10/2023

The Booming Breast Cancer Market and Promising Therapies: Key Trends and…

In order to reduce the rates of breast cancer incidence, the first and foremost step for medical researchers and healthcare experts is to gain complete disease insights. Without understanding the traits, underlying causes, and action mechanism of this cancer form, they cannot determine breast cancer risk factors and formulate effective treatment solutions. Being a complex disorder, it gets difficult for them to get a 360-degree disease overview. This is when they seek consulting services from…
PR Newswire
02/10/2023

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New…

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, commented, "This approval marks a major milestone for the Pompe disease community in the United States. Bringing this new treatment option to market has required immense dedication and strong partnership between the WuXi Biologics team and Amicus, relying on our shared dedication to patients and our ability to execute on our vision to bring high quality therapies to the rare disease community. Over many years of…
PR Newswire
02/10/2023

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative…

FLASH radiotherapy is an advanced form of radiation therapy that delivers extremely high doses of radiation in a fraction of a second, reducing treatment time and damage to surrounding healthy tissues. This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment. Developed in collaboration with CHUV (Lausanne University Hospital,Switzerland ) and based on CERN technology (European...
PR Newswire
01/10/2023

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association…

Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management. Powered by SIBIONICS CGM technology, the KS1 stands as the world's pioneer in combining sensor and transmitter functions, offering continuous real-time monitoring ketone levels up to 14 days. Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management. Powered by SIBIONICS CGM…
PR Newswire
01/10/2023

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose…

Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST PARIS and CAMBRIDGE, Mass., Sept.29, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a...
Nasdaq GlobeNewswire
29/09/2023

FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing…

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept.29, 2023(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody...
Nasdaq GlobeNewswire
29/09/2023

AB Science today reports its revenues for the first half of 2023 and provides an…

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development strategy based on two platforms: the late-stage masitinib platform and the new microtubule platform Masitinib platform: License search for masitinibStudies in amyotrophic lateral sclerosis (ALS), mastocytosis, MCAS and Covid-19 are ongoingOngoing EMA and Health Canada procedures for conditional authorisation of...
Nasdaq GlobeNewswire
29/09/2023

Oxurion Publishes First Half 2023 Results

Regulated InformationLeuven, BELGIUM, Boston, MA, US –September 29 , 2023 – 7 .00PM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023.The half-year report is available in the “ Investors ” section of the Company's website and can...
Nasdaq GlobeNewswire
29/09/2023

Casino Group: Extension of the lock-up agreement deadline

Extension of the deadline to enter into a lock-up agreement Paris, 29 September 2023Further to its press release dated 28 July 2023 relating to the execution of an agreement in principle with certain secured creditors, Casino announces the extension of the deadline to enter into a lock-up agreement with its creditors until the 3rd of October, i.e. an agreement pursuant to which the signatories commit to support and take all steps and actions reasonably necessary to implement and...
Nasdaq GlobeNewswire
29/09/2023

Softgel Capsules Market worth $1.5 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238329912 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238329912 Browse in-depth TOC on "Softgel Capsules Market" 155 - Tables 38 - Figures 173 - Pages Softgel Capsules Market Scope: In 2022, the gelatin segment accounted for the largest market share of the softgel capsules market based on material type. Based on...
PR Newswire
29/09/2023

Total number of shares and voting rights in Zealand Pharma at September 29, 2023

Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at...
Nasdaq GlobeNewswire
29/09/2023

L'Oréal groupe OFFICIALLY OPENS NEW UK HEADQUARTERS IN WHITE CITY

As L'Oréal Groupe celebrates reaching a historic milestone of 90 years in the UK, the number one beauty player has moved all 1,000+ head office employees to a new head office in Gateway Central, at the heart of the thriving White City Innovation District. As L'Oréal Groupe celebrates reaching a historic milestone of 90 years in the UK, the number one beauty player has moved all 1,000+ head office employees to a new head office in Gateway Central, at the heart of the thriving White…
PR Newswire
29/09/2023

Novartis completes divestment of 'front of eye' ophthalmology assets

Divestment includes Xiidra ® ,on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic areas for future growth Basel, September 29th, 2023— Novartis today announced that it has completed its divestment of 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in...
Nasdaq GlobeNewswire
29/09/2023

Jandy Adds More Horsepower to its Pump Lineup

Now offering pumps with a horsepower as high as 3.8 THP, Jandy offers a wide-range of variable-speed pumps to suit any system. The newest pumps in both the FloPro™ and ePump™ series are designed with advanced technologies that cater to pool owners seeking more power and efficiency in running their pools, as well as pool professionals looking for easy installation and simple programming. Now offering pumps with a horsepower as high as 3.8 THP, Jandy offers a wide-range of variable-speed pumps…
PR Newswire
29/09/2023

Pending 510(k) Decision for Leo Cancer Care Paves the Way for New Era of Patient…

Leo Cancer Care CEO Stephen Towe said: "This is a highly significant milestone for our company; 510(k) submission is an important step forward in our drive to see cancer therapy delivered to patients in a more human way." Leo Cancer Care CEOStephen Towesaid: "This is a highly significant milestone for our company; 510(k) submission is an important step forward in our drive to see cancer therapy delivered to patients in a more human way." Treatment in the upright position The…
PR Newswire
29/09/2023

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement…

The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discoveryAI technology products projected to be in marketplace in 2024Phase 1/2 human studies of pancreatic cancer and other solid tumors with poor longevity projected to begin second half of 2024 LOS ANGELES, Sept.29, 2023(GLOBE NEWSWIRE) -- Renovaro Biosciences...
Nasdaq GlobeNewswire
29/09/2023

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th…

Biomarker Analyses Biomarker Analyses IgA-containing immune complexes (IgA-IC) have previously been shown to accumulate in renal tissue, where they trigger inflammation and scarring in the glomeruli. Investigation of the effect of Nefecon on circulating levels of IgA-IC in the Part A population of the NefIgArd clinical trial (n=160) revealed that patients treated with Nefecon 16mg/day exhibited a statistically significant decrease in IgA-IC levels compared to patients who received...
PR Newswire
29/09/2023
Altri  Comunicati